Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)-guided neoadjuvant (n) treatment for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis

Tag: Solid Tumors

BeOne is advancing a solid tumor pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. Among these are tislelizumab, a monoclonal antibody against PD-1 and ociperlimap, a monoclonal antibody against TIGIT.

Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind and inhibit PD‑1. Watch the mode of action (MoA) video to learn more.

Video
29 May 2024